92 related articles for article (PubMed ID: 21365738)
1. Recommendations for economic evaluations of non-pharmacological arthritis care: results from the CARE VI meeting 2010.
van den Hout WB; Bremander A; Vliet Vlieland TP
Musculoskeletal Care; 2011 Jun; 9(2):120-3. PubMed ID: 21365738
[No Abstract] [Full Text] [Related]
2. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus.
Graf von der Schulenburg JM; Greiner W; Jost F; Klusen N; Kubin M; Leidl R; Mittendorf T; Rebscher H; Schoeffski O; Vauth C; Volmer T; Wahler S; Wasem J; Weber C;
Value Health; 2008; 11(4):539-44. PubMed ID: 18194408
[No Abstract] [Full Text] [Related]
3. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
4. Outcome measurement in economic evaluation.
Johannesson M; Jönsson B; Karlsson G
Health Econ; 1996; 5(4):279-96. PubMed ID: 8880165
[No Abstract] [Full Text] [Related]
5. Determinants of health economic decisions in actual practice: the role of behavioral economics. Summary of the presentation given by Professor Daniel Kahneman at the ISPOR 10th Annual International Meeting First Plenary Session, May 16, 2005, Washington, DC, USA.
Value Health; 2006; 9(2):65-7. PubMed ID: 16626409
[No Abstract] [Full Text] [Related]
6. Preferences for health outcomes and cost-utility analysis.
Torrance GW
Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
[TBL] [Abstract][Full Text] [Related]
7. [German recommendations for health care economic evaluation studies. Revised version of the Hannover consensus. Hannover Consensus Group].
Med Klin (Munich); 2000 Jan; 95(1):52-5. PubMed ID: 10668346
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case.
Maetzel A; Tugwell P; Boers M; Guillemin F; Coyle D; Drummond M; Wong JB; Gabriel SE;
J Rheumatol; 2003 Apr; 30(4):891-6. PubMed ID: 12672224
[TBL] [Abstract][Full Text] [Related]
9. The use of quality-adjusted life-years in cost-effectiveness studies.
Sculpher M
Allergy; 2006 May; 61(5):527-30. PubMed ID: 16629779
[No Abstract] [Full Text] [Related]
10. Cost and outcomes analysis.
King JT; Ratcheson RA
Neurosurg Clin N Am; 1998 Jul; 9(3):629-40. PubMed ID: 9668193
[TBL] [Abstract][Full Text] [Related]
11. Money matters: what to look for in an economic analysis.
Dijksman LM; Poolman RW; Bhandari M; Goeree R; Tarride JE;
Acta Orthop; 2008 Feb; 79(1):1-11. PubMed ID: 18283565
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
[TBL] [Abstract][Full Text] [Related]
13. A guide to health economic evaluations.
Drug Ther Bull; 2010 Sep; 48(9):105-8. PubMed ID: 20810710
[TBL] [Abstract][Full Text] [Related]
14. Willingness to pay in the context of an economic evaluation of healthcare programs: theory and practice.
Gafni A
Am J Manag Care; 1997 May; 3 Suppl():S21-32. PubMed ID: 10180338
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluations and diabetes.
Pathak DS; Burke TA
Pharm Pract Manag Q; 1998 Jan; 17(4):17-24. PubMed ID: 10174745
[TBL] [Abstract][Full Text] [Related]
16. [Methods for cost-effectiveness evaluation of intensive care].
Heslet L; Andersen JS; Keiding H
Ugeskr Laeger; 2007 Feb; 169(8):721-4. PubMed ID: 17313927
[TBL] [Abstract][Full Text] [Related]
17. Theory and methods of economic evaluation of health care.
Johannesson M
Dev Health Econ Public Policy; 1996; 4():1-245. PubMed ID: 10158916
[No Abstract] [Full Text] [Related]
18. Disability Adjusted Life Years (DALYs) and rehabilitation.
Jelsma J; De Weerdt W; De Cock P
Disabil Rehabil; 2002 May; 24(7):378-82. PubMed ID: 12022788
[TBL] [Abstract][Full Text] [Related]
19. Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis.
Bansback N; Maetzel A; Drummond M; Anis A; Marra C; Conway P; Boers M; Tugwell P; Boonen A
J Rheumatol; 2007 May; 34(5):1178-83. PubMed ID: 17477483
[TBL] [Abstract][Full Text] [Related]
20. Cost, effectiveness, and cost-effectiveness.
Diamond GA; Kaul S
Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):49-54. PubMed ID: 20031812
[No Abstract] [Full Text] [Related]
[Next] [New Search]
